GovTribe
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Contract IDV Awards
Help
Indefinite Delivery Contract HHSO100201300010I
Award Date
9/9/13
Last Date to Order
9/8/18
Overview
Buyer Personas
Industry Personas
Buyer Personas In this Market
Activity
6
Contract IDVs
Contract Awards
2
Transactions
6
Price Lists
Opportunity Stack
1
Similar IDVs
Funding Federal Agency
Department of Health and Human Services
Contracting Federal Agency
Office of the Assistant Secretary for Preparedness and Response
Awardee
Elusys Therapeutics Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
AN13 - Health R&D Services; Health Care Services; Experimental Development
Set-Aside Type
Partial Small Business
Federal Contract Vehicle
Not listed
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
Not listed
HHSO100201300010I
Indefinite Delivery Contract
2
Federal Contract Awards
Description
Update #1
Posted 9/8/13, 12:00 AM
Mod #
Description
Reason For Modification
Federal Obligation
(Click to sort descending)
Date
(Click to sort ascending)
5
ELUSYS THERAPEUTICS, INC
Other Administrative Action
$0
11/6/15
4
ELUSYS THERAPEUTICS, INC
Other Administrative Action
$0
9/1/15
3
ELUSYS THERAPEUTICS, INC
Other Administrative Action
$0
8/19/15
2
ELUSYS THERAPEUTICS, INC
Other Administrative Action
$0
12/11/14
1
ELUSYS THERAPEUTICS, INC
Other Administrative Action
$0
9/16/13
Name
Description
Awardee
Potential Value
(Click to sort descending)
Award Date
(Click to sort descending)
Completion Date
(Click to sort descending)
Updated At
(Click to sort descending)
Delivery Order HHSO100201300010I-75A50118F33002
This is a firm-fixed price delivery order contract awarded by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Elusys Therapeutics Inc., a self-certified small disadvantaged business. The contract, valued at $24,501,100.00, is for "ANTHIM LETTER CONTRACT" and "FOR OTHER FUNCTIONS" services in the area of biomedical research and development. The contract has no set-aside designation and the period of performance runs through January 31, 2022. Elusys Therapeutics specializes in advanced biomedical products and services, and has previously received contracts from HHS, the Department of Defense, and the National Institutes of Health.
Elusys Therapeutics Inc.
$24.5m
4/16/18
1/31/22
1/27/22
Delivery Order HHSO100201300010I-HHSO10033001T
This is a federal contract award from the U.S. Department of Health and Human Services (HHS) to Elusys Therapeutics Inc., a for-profit organization and manufacturer of goods. The contract, valued at $44,971,900.00, is for "OTHER FUNCTIONS" and is a Firm Fixed Price Delivery Order with no set-aside designation. Elusys Therapeutics Inc. specializes in biomedical research and development, with a focus on advanced technology. The contract is related to the "ANTHIM" product, which suggests it may be for the development or procurement of biomedical countermeasures. The prime contractor, Elusys Therapeutics Inc., has successfully expanded its customer base over time, receiving awards from both the Department of Defense (DOD) and HHS, with HHS being the most frequent buyer.
Elusys Therapeutics Inc.
$45.0m
11/2/15
9/30/21
5/6/21
Name
Description
Solicitation Number
Federal Agency
Type
Posted Date
(Click to sort descending)
Anthrax Antitoxins for the Treatment of Inhalational Anthrax
Added: Jun 15, 2012 3:26 pm The Department of Health and Human Services (HHS) has the responsibility of maintaining a definitive supply of medical countermeasures - or the forward deployment of same - for use in national medical emergencies declared by the Secretary of HHS. HHS has a requirement to acquire, store, and distribute medical countermeasures that will mitigate injuries caused by exposure to chemical, biological teat agents, physical radiologic and nuclear exposures. The Biomedical Advanced Research and Development Authority (BARDA) within the Office of the Assistant Secretary for Preparedness & Response (ASPR) has a specific need for antax antitoxin products to treat individuals with symptomatic antax disease resulting from aerosol release of Bacillus antacis (B. antacis) spores.
RFP-12-100-SOL-00026
Department of Health and Human Services Immediate Office of the Secretary
Award Notice 1/1
6/15/12, 3:26 PM